Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 8238 results

  1. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  29 July 2026

  2. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-IPG10465 Expected publication date: TBC

  3. Needle Muscle Biopsy

    Topic prioritisation

  4. Sentinel Node Biopsy approved for pathological staging of clinically T1-T2 N0 oral cancer

    Topic prioritisation

  5. Digital tools and platforms to support the early detection and initial diagnosis of hearing loss

    Awaiting development Reference number: GID-HTE10088 Expected publication date: TBC

  6. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

  7. Retatrutide for managing overweight and obesity [ID6644]

    Awaiting development Reference number: GID-TA11845 Expected publication date: TBC

  8. Digital flexor tenotomy for diabetic foot

    Topic prioritisation

  9. Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  18 March 2026

  10. Dermal allograft augmentation in proximal humerus fracture fixation

    Topic prioritisation

  11. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

  12. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    Awaiting development Reference number: GID-TA11858 Expected publication date: TBC

  13. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

  14. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

  15. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    In development Reference number: GID-TA10960 Expected publication date: TBC